Get the Stockscreener App
5.30
2.51%
0.13
After Hours:
5.08
-0.22
-4.15%
Monte Rosa Therapeutics Inc stock is traded at $5.30, with a volume of 219.76K.
It is up +2.51% in the last 24 hours and down -14.10% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$5.17
Open:
$5.05
24h Volume:
219.76K
Relative Volume:
0.81
Market Cap:
$325.28M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-2.0623
EPS:
-2.57
Net Cash Flow:
$-67.76M
1W Performance:
-10.92%
1M Performance:
-14.10%
6M Performance:
-24.82%
1Y Performance:
+10.65%
1-Day Range:
$4.9202
$5.48
1-Week Range:
$4.9202
$6.10
52-Week Range:
$2.44
$8.84
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Learn to Evaluate (GLUE) using the Charts - Stock Traders Daily
Potential Price Increase for Monte Rosa Therapeutics Inc (GLUE) After Recent Insider Activity - Knox Daily
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock By Investing.com - Investing.com South Africa
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock By Investing.com - Investing.com Australia
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock - Investing.com India
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock - Investing.com
Can you now get a good deal on Monte Rosa Therapeutics Inc’s shares? - US Post News
We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth - Simply Wall St
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Up 9.7% in August - Defense World
Meeder Asset Management Inc. Purchases Shares of 10,050 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Versant Venture Capital Vi, L. Sells 541,897 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock - Defense World
Versant entities sell over $3.4 million in Monte Rosa Therapeutics stock - Investing.com Australia
Wedbush Reiterates Outperform Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Major Shareholder Versant Venture Capital Vi, L. Sells 9,269 Shares - MarketBeat
Versant entities sell over $3.4 million in Monte Rosa Therapeutics stock - Investing.com
Versant entities sell over $3.4 million in Monte Rosa Therapeutics stock - Investing.com India
Monte Rosa Therapeutics' (GLUE) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 3.3% - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 3.3% - Defense World
Monte Rosa Therapeutics Inc’s Banking’s 100-Day Moving Average at 4.77: Will the Stock Break Through? - The InvestChronicle
Market Insights: Monte Rosa Therapeutics Inc (GLUE)’s Notable Drop of -3.44, Closing at 6.17 - The Dwinnex
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth - Yahoo Finance
Monte Rosa begins trial of new autoimmune disease therapy - Investing.com India
Monte Rosa begins trial of new autoimmune disease therapy - Investing.com
Monte Rosa begins trial of new autoimmune disease therapy By Investing.com - Investing.com Australia
Monte Rosa begins trial of new autoimmune disease therapy By Investing.com - Investing.com UK
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study - GlobeNewswire
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study - StockTitan
Monte Rosa Therapeutics (NASDAQ:GLUE) PT Lowered to $17.00 - Defense World
Vanguard Group Inc. Grows Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics (NASDAQ:GLUE) PT Lowered to $17.00 at Wells Fargo & Company - MarketBeat
Monte Rosa Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Monte Rosa Therapeutics: Q2 Earnings Snapshot - San Francisco Chronicle
Monte Rosa Therapeutics: Q2 Earnings Snapshot - New Haven Register
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics: Q2 Earnings Snapshot - Thehour.com
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - StockTitan
Price T Rowe Associates Inc. MD Has $35.93 Million Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - MarketBeat
Price T Rowe Associates Inc. MD Buys 155,880 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Acadian Asset Management LLC Raises Stock Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) & Finch Therapeutics Group (NASDAQ:FNCH) - Defense World
Head to Head Comparison: TScan Therapeutics (NASDAQ:TCRX) and Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Increases By 29.3% - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Up 29.3% in June - MarketBeat
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Increases By 29.3% - American Banking and Market News
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day - Bakersfield.com
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):